Filing Details

Accession Number:
0000899243-16-033677
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-16 16:10:07
Reporting Period:
2016-11-14
Filing Date:
2016-11-16
Accepted Time:
2016-11-16 16:10:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1629137 Global Blood Therapeutics Inc. GBT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1192591 J Charles Homcy C/O Global Blood Therapeutics, Inc.
400 East Jamie Court, Suite 101
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-11-14 0 $0.00 0 No 4 S Indirect See Footnote
Common Stock Disposition 2016-11-14 0 $0.00 0 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 14,611 Direct
Footnotes
  1. The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of Third Rock Ventures II, L.P. ("TRV II"). The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
  2. The reporting person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of Third Rock Ventures III, L.P. ("TRV III"). The reporting person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
  3. Includes 14,611 shares received by the Reporting Person in a distributions-in-kind by TRV II on November 3, 2016, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.